Centiva Capital’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Centiva Capital’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-50,000	Closed	-$1.92M	–	2253
2023 Q2	$1.92M	Buy	+50,000	New	+$1.28M	0.04%	399

Centiva Capital's KDNY Position: Q3 2023 in Review

Centiva Capital sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 61,734 shares — an estimated $2.37M sold.

Centiva Capital first reported a position in KDNY in Q2 2023 and held it in 1 quarter. The position peaked at $2.37M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Centiva Capital reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Centiva Capital sold 61,734 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $2.37M.
Centiva Capital first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
Centiva Capital's Chinook Therapeutics, Inc. Common Stock position peaked at $2.37M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Centiva Capital's 13F filing for Q3 2023, filed 14 Nov 2023.